# Japan Asia Investment

> Japan Asia Investment is a VC fund in Tokyo backing Medical and Health Care. See 36 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 36
- Last investment: Mar 2020
- Lead investor: 11%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/japan-asia-investment-co.-ltd./about/
- Website: http://www.jaic-vc.co.jp

Japan Asia Investment is a VC fund in Tokyo focused on Medical and Health Care. JAIC is Japan's largest independent venture capital firm and has accumulated experience and know-how over a period of 15 years as a pioneer of venture capital investments in Asia. Building on such strengths, they are establishing a globally linked organization that pursues investment opportunities centering on the three regions of Japan, Asia,and the United States.

## Contacts

5 contacts available for Japan Asia Investment. Shizune tracks 7 team members at Japan Asia Investment. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/japan-asia-investment?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $6M–$283M |
| Series C | $5M–$32M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 6 | 17% |
| Health Care | 6 | 17% |
| Biotechnology | 6 | 17% |
| Internet | 5 | 14% |
| Software | 5 | 14% |

66 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 11 | 31% |
| Series B | 10 | 28% |
| Series C | 4 | 11% |
| Seed | 2 | 6% |
| Series A | 2 | 6% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 20 | 56% |
| United States | 8 | 22% |
| China | 1 | 3% |
| Romania | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Hiroyuki Misawa | Managing Director | 11 | https://shizune.co/investors/profile/hiroyuki-misawa |
| Hidetaka Fukuzawa | Managing Directors | 0 | https://shizune.co/investors/profile/hidetaka-fukuzawa |
| Keizai Doyukai | Founder | 0 | https://shizune.co/investors/profile/keizai-doyukai |
| Kenjiro Kanaya | Standing Corporate Auditor | 0 | https://shizune.co/investors/profile/kenjiro-kanaya |
| Makoto Isshi | Senior Managing Director | 0 | https://shizune.co/investors/profile/makoto-isshi |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| KIC holdings | KIC Holdings engages in asset management, securitization, investment, advisory services,and real estate development businesses. They offer detailed services for due diligence, acquisition, financing, management planning, and asset management for medium- to large-size distribution centres, warehouses, and trunk rooms. |  | Venture - Series Unknown | Mar 01, 2020 |  |
| Integral Geometry Science | Integral Geometry Science is a specialized manufacturer of measuring equipment and signal / image processing software. | $70.1M |  | Sep 13, 2019 |  |
| REGiMMUNE | REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens throughinduction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE).Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline.In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment. | $92.1M | Series E | May 10, 2017 |  |
| FacePeer | FacePeer is looking for people who want to challenge at startup. | $28.3M |  | May 10, 2017 |  |
| Laxus Technologies | Laxus Technologies is an E-Commerce start up. | $198.4M | Series B | Jan 25, 2017 |  |
| Ligua | LIGUA provides consulting services. | $32.5M |  | May 02, 2016 |  |
| TORICO | TORICO Operates an online platform and application, which sells books, e-books, and more. The company was founded in 2005 and is based in Chisoda, Timis. | $22.7M |  | Mar 10, 2016 |  |
| FunPep | FunPep is an Industry-university collaboration bioventure company. | $17M |  | Nov 30, 2015 |  |
| Aoi.co | Aoi.Co has acquired over 3,000 students as users to date and unveiled that the entrance exam passing rate of users for their preferred universities has reached 86.3%. The firm plans to use the funds to strengthen its system development capability and introduce a learning state monitoring app for parents in September. | $39.7M | Series B | Nov 25, 2015 |  |
| Eltes | Eltes specializes in providing solutions by big data analysis specialized in risk detection. | $75.8M |  | Oct 02, 2015 |  |

10 of 36 investments shown.

## Co-investors
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund, 7 deals together
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund, 7 deals together
- [KSP](https://shizune.co/investors/profile/ksp) — VC Fund, 4 deals together
- [Resona Capital](https://shizune.co/investors/profile/resona-capital) — VC Fund, 4 deals together
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund, 4 deals together
- [HBM Healthcare Investments](https://shizune.co/investors/profile/hbm-healthcare-investments-ag) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Japan](https://shizune.co/investors/biotechnology-investors-japan)
- [Biotechnology VC Funds in Japan](https://shizune.co/investors/biotechnology-vc-funds-japan)
- [Biotech VC Funds in Japan](https://shizune.co/investors/biotech-vc-funds-japan)
- [Video Games Investors in Japan](https://shizune.co/investors/video-games-investors-japan)
- [Video Games VC Funds in Japan](https://shizune.co/investors/video-games-vc-funds-japan)

## FAQ

### What does Japan Asia Investment invest in?

Japan Asia Investment invests primarily in Medical, Health Care and Biotechnology startups, most often at Funding Round and Series B stage. Most of the 36 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Japan Asia Investment's check size?

Japan Asia Investment typically joins rounds of $6M–$283M at Series B and $5M–$32M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Japan Asia Investment participates in.

### How do I contact Japan Asia Investment?

Public channels for Japan Asia Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Japan Asia Investment?

The team at Japan Asia Investment includes Hiroyuki Misawa (Managing Director), Hidetaka Fukuzawa (Managing Directors) and Keizai Doyukai (Founder), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co